v3.26.1
Basis of Presentation (Tables)
3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
Schedule of Indefinite-Lived Intangible Assets

U.S. Method Patent   13.4 years
     
Web Domain   Indefinite life
     
Trademark   Indefinite life
Schedule of Revenue Recognition

The Company’s revenues consisted of the following:

 

   2026   2025 
  

For the Three Months

Ended

March 31,

 
   2026   2025 
Allergy Diagnostic Kit Sales  $228,770   $264,913 
Integrated Service Program   374,501    162,502 
Immunotherapy Treatment Sales   91,070    97,329 
Clinical Study Revenue   -    89,100 
Subscription Revenue   11,948    9,285 
Shipping and handling   11,640    9,970 
Training and Other Revenue   10,756    12,320 
Total Revenue  $728,685   $645,419